Stocks Health care BIAF

NASDAQ · Health care

bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies, Inc. brought in $5.9M of revenue over the twelve months to June 30, 2026, down 23.2% from a year earlier. It posted a net loss of $15.2M. In fiscal 2025 capital spending exceeded operating cash flow by $9.4M. At June 30, 2026 it held $2.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Watch BIAF in 60 seconds

Follow BIAF

Free, no password. An email when BIAF files with the SEC.

Key facts about bioAffinity Technologies, Inc.

Net worth

bioAffinity Technologies, Inc. has a market value (market cap) of $19.6M at the latest share price, and shareholders' equity of $3.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $6.2M (-34.2% year on year), with a net loss of $14.9M. Over the 12 months to June 30, 2026: revenue $5.9M, net loss $15.2M.

Cash flow

In fiscal 2025 operations used $9.3M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

What bioAffinity Technologies, Inc. does

bioAffinity Technologies, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker BIAF.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where BIAF ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What bioAffinity Technologies, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. October 6, 2026
   Other event 8-K
2. September 30, 2026
   Other event 8-K
3. September 29, 2026
   Preliminary proxy statement PRE 14A
4. September 22, 2026
   Other event 8-K
5. September 17, 2026
   Other event 8-K
6. September 11, 2026
   Investor disclosure 8-K
7. September 9, 2026
   Other event 8-K
8. September 3, 2026
   Other event 8-K
9. September 3, 2026
   Shelf registration to sell securities (amended) S-3/A
10. September 1, 2026
    Other event 8-K

Recent insider filings (Forms 3, 4 and 144): 8, the latest on September 25, 2025. Insider transactions on SEC

Insider trades

What the people running bioAffinity Technologies, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BIAF

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BIAF

What does bioAffinity Technologies, Inc. do?

bioAffinity Technologies, Inc. is a company in the Health care sector, listed on NASDAQ as BIAF. Its shares trade on NASDAQ under the ticker BIAF.

What is bioAffinity Technologies, Inc.'s net worth?

bioAffinity Technologies, Inc. has a market value (market cap) of $19.6M at the latest share price, and shareholders' equity of $3.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is bioAffinity Technologies, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $15.2M on revenue of $5.9M.

How much revenue does bioAffinity Technologies, Inc. make?

Over the twelve months to June 30, 2026 bioAffinity Technologies, Inc. reported revenue of $5.9M. That is 23.2% less than a year earlier.

When did bioAffinity Technologies, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 6, 2026.

Similar companies

Compare BIAF with

Compare BIAF with any company

Follow BIAF

Get an email when bioAffinity Technologies, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BIAF

Free, no password. An email when BIAF files with the SEC.

Where the numbers come from

Financial figures are the values bioAffinity Technologies, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.